30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Year in Review

2014 Revenue: Bacterin

4Q14 revenue: $9.1MM, +10%

2014 revenue: $35.3MM, +7%


  • 3Demin portfolio generated >$250,000 since launch
  • Claims total market for products (like OsteoSponge, 3Demin) is ~$410MM
  • Claims share for demineralized bone matrix products ~6% of U.S. market
  • In 1Q, announced renewal of Novation contract as well as distribution agreement with Spartan Medical to supply biologic product portfolio to U.S. Departments of Defense and Veteran's Affairs
  • Ended 2014 with 28 productive reps; planning 39 for full-year 2015
  • Two planned 2015 launches include general ortho and foot/ankle indications
  • Current M&A activity (e.g. Integra/Seaspine spinoff; Zimmer Biomet; Wright/Tornier) creating opportunities to enter hospitals where company has not previously had contracts